In recent research, it was shown that combining PD-1/PD-L1 inhibitors with CAR T-cell treatment enhanced the response rate and overall survival of patients with relapsed or resistant diffuse large B-cell lymphoma (DLBCL). Here, PDCD1 is linked to diffuse large B-cell lymphoma.